• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Initial practice of left atrial appendage closure device in Japan; single-center experience
CONCLUSIONS: In this initial Japanese experience, LAAC therapy for high bleeding risk patients with NVAF seems feasible. Optimal antithrombotic regimens are warranted for better clinical outcomes.PMID:35094892 | DOI:10.1016/j.jjcc.2022.01.004
Source: Journal of Cardiology - January 31, 2022 Category: Cardiology Authors: Masato Fukunaga Akihiro Isotani Shinichi Shirai Naoto Murakami Miho Nakamura Takashi Morinaga Kenichi Ishizu Kazuki Kitano Tatsuhiro Kataoka Masaomi Hayashi Kenichi Hiroshima Kenji Ando Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Comparative Safety and Effectiveness of Apixaban vs. Warfarin in Oral Anticoagulant-Na ïve Japanese Patients With Non-Valvular Atrial Fibrillation　- A Retrospective Chart Review Study
CONCLUSIONS: The benefit of apixaban over warfarin for the reduction in risk of major bleeding and stroke/SE could be generalizable to daily clinical practice and to patients with reduced renal function.PMID:34897136 | DOI:10.1253/circj.CJ-21-0682
Source: Circulation Journal - December 13, 2021 Category: Cardiology Authors: Yukihiro Koretsune Haruhiko Hoshino Yukako Matsuo Tatsuki Ibuki Takeshi Morimoto Source Type: research

Effect of Cancer on Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillation 　- Substudy of the ANAFIE Registry
CONCLUSIONS: Active cancer had no effect on stroke/SEE incidence in elderly NVAF patients, but those with cancer had higher incidences of major bleeding events and all-cause death than those without cancer.PMID:34853279 | DOI:10.1253/circj.CJ-21-0631
Source: Circulation Journal - December 2, 2021 Category: Cardiology Authors: Takanori Ikeda Takeshi Yamashita Masaharu Akao Hirotsugu Atarashi Yukihiro Koretsune Ken Okumura Wataru Shimizu Hiroyuki Tsutsui Kazunori Toyoda Atsushi Hirayama Masahiro Yasaka Takenori Yamaguchi Satoshi Teramukai Tetsuya Kimura Jumpei Kaburagi Atsushi T Source Type: research

Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves 　- Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry
CONCLUSIONS: Approximately 30% of patients with AF and BPV replacement were treated with DOAC. The risks of major bleeding and stroke or systemic embolism were similar between warfarin- and DOAC-treated patients with AF who had BPV replacement. Treatment with DOACs could be an alternative to warfarin in this population.PMID:34719560 | DOI:10.1253/circj.CJ-21-0564
Source: Circulation Journal - November 1, 2021 Category: Cardiology Authors: Chisato Izumi Makoto Miyake Tomoyuki Fujita Tadaaki Koyama Hidekazu Tanaka Kenji Ando Tatsuhiko Komiya Masaki Izumo Hiroya Kawai Kiyoyuki Eishi Kiyoshi Yoshida Takeshi Kimura Ryuzo Nawada Tomohiro Sakamoto Yoshisato Shibata Toshihiro Fukui Kenji Minatoya Source Type: research

Genes, Vol. 12, Pages 1537: Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients
Kazuyuki Nagatsuka The genotypes of vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) can influence therapeutic warfarin doses. Conversely, nongenetic factors, especially renal function, are associated with warfarin maintenance doses; however, the optimal algorithm for considering genes and renal dysfunction has not been established. This single-center prospective cohort study aimed to evaluate the factors affecting warfarin maintenance doses and develop pharmacogenetics-guided algorithms, including the factors of renal impairment and others. To commence, 176 outpatients who were prescrib...
Source: Genes - September 28, 2021 Category: Genetics & Stem Cells Authors: Tomotaka Tanaka Masafumi Ihara Kazuki Fukuma Haruko Yamamoto Kazuo Washida Shunsuke Kimura Akiko Kada Shigeki Miyata Toshiyuki Miyata Kazuyuki Nagatsuka Tags: Article Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Effectiveness and Safety of Rivaroxaban by General Practitioners 　- A Multicenter, Prospective Study in Japanese Patients With Non-Valvular Atrial Fibrillation (GENERAL)
CONCLUSIONS: The low incidence of adverse events, including stroke/SE and bleeding, in patients prescribed rivaroxaban by general practitioners supports its use as a safe and efficacious treatment in the standard clinical care of high-risk patient populations.PMID:33814525 | DOI:10.1253/circj.CJ-20-1244
Source: Circulation Journal - April 5, 2021 Category: Cardiology Authors: Kengo Kusano Nobuyoshi Sugishita Masaharu Akao Hikari Tsuji Kunihiko Matsui Shinya Hiramitsu Yutaka Hatori Hironori Odakura Hiroyuki Kamada Koji Miyamoto Hisao Ogawa Source Type: research

Pages: 1  2  3  4  5